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Abstract
Background: Bladder cancer is the ninth most common type of cancer worldwide. In the past, radical cystectomy
via open surgery has been considered the gold-standard treatment for muscle invasive bladder cancer. However, in
recent years there has been a progressive increase in the use of robot-assisted laparoscopic radical cystectomy. The
aim of the current project is to investigate the surgical, oncological, and functional outcomes of patients with
bladder cancer who undergo radical cystectomy comparing three different surgical techniques (robotic-assisted,
laparoscopic, and open surgery). Pre-, peri- and post-operative factors will be examined, and participants will be
followed for a period of up to 24 months to identify risks of mortality, oncological outcomes, hospital readmission,
sexual performance, and continence.
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Methods: We describe a protocol for an observational, prospective, multicenter, cohort study to assess patients
affected by bladder neoplasms undergoing radical cystectomy and urinary diversion. The Italian Radical Cystectomy
Registry is an electronic registry to prospectively collect the data of patients undergoing radical cystectomy
conducted with any technique (open, laparoscopic, robotic-assisted). Twenty-eight urology departments across Italy
will provide data for the study, with the recruitment phase between 1st January 2017-31st October 2020.
Information is collected from the patients at the moment of surgical intervention and during follow-up (3, 6, 12,
and 24 months after radical cystectomy). Peri-operative variables include surgery time, type of urinary diversion,
conversion to open surgery, bleeding, nerve sparing and lymphadenectomy. Follow-up data collection includes
histological information (e.g., post-op staging, grading, and tumor histology), short- and long-term outcomes (e.g.,
mortality, post-op complications, hospital readmission, sexual potency, continence etc).
Discussion: The current protocol aims to contribute additional data to the field concerning the short- and long-
term outcomes of three different radical cystectomy surgical techniques for patients with bladder cancer, including
open, laparoscopic, and robot-assisted. This is a comparative-effectiveness trial that takes into account a complex
range of factors and decision making by both physicians and patients that affect their choice of surgical technique.
Trial registration: ClinicalTrials.gov, NCT04228198. Registered 14th January 2020- Retrospectively registered.
Keywords: Cancer, Neoplasm; bladder, Urinary, Robotic, Surgery, Bladder reconstruction, Prostate
Background
Epidemiology of bladder cancer
Bladder cancer is the ninth most common type of cancer
worldwide, with 75% of the total burden occurring in
men [1]. In Europe the age-standardized incidence rate
is 19.1 for men and 4.0 for women, and mortality rates
(per 100,000 persons years) are 3.2 for men and 0.9 for
women [2]. Bladder cancer increases with age and, al-
though it is higher in men than women [1], incidence in
both sexes is expected to increase in European countries
[3]. Cigarette smoking has been identified as one of the
main risk factors for bladder cancer [3, 4], and incidence
rates are higher in more developed countries [5].
At initial diagnosis, cancer neoplasms present as a
non-muscle-invasive pathology in 70–75% of cases, and
a muscle-invasive form in about a quarter of cases [6].
In about one third of patients with a diagnosis of
muscle-invasive bladder tumor, the neoplasm is found to
be a metastasis that was not identified during treatment
of the primary tumor; in particular, lymph node involve-
ment is identified during surgery in about 25% of pa-
tients receiving a radical cystectomy [7].
Radical cystectomy: the gold standard
Since the 1960s, treatment with radical cystectomy has
been the gold standard for invasive tumors of the blad-
der wall and is indicated for non-muscle-invasive blad-
der neoplasms with a high risk of progression or relapse
that are non-responsive to intra-bladder immunotherapy
(intravesical instillation of Bacillus Calmette-Guerin
(BCG)), and in cases of pelvic neoplasms infiltrating the
bladder [7–9]. In urology, cystectomy is considered to be
one of the most technically challenging oncological in-
terventions. Radical cystectomy involves removal of the
entire bladder and lymph node dissection. In men, the
prostate is often removed as well as the seminal vesicles,
while in women the uterus, ovaries, and a small portion
of the vagina and fallopian tubes are removed. Surgery
includes the removal phase, followed by a reconstruction
phase, which may consist of incontinent (using an ileal
conduit) or continent (using a urethral or cutaneous
neobladder) urinary diversion. The type of urinary diver-
sion chosen varies according to the cancer stage and
grade, prognosis, comorbidity, and functional status of
the patient as well as potential contraindications to cre-
ating a neobladder [10, 11]. There are many factors that
can be used to evaluate the success of treatment, includ-
ing peri-operative outcomes (such as blood loss, mortal-
ity, hospital stay, complication rates etc), and short- or
long-term outcomes (including overall survival,
recurrence-free survival, and cancer-specific survival), as
well as functional outcomes (such as continence and
sexual potency).
New, minimally invasive approaches and treatments:
robot-assisted laparoscopic radical cystectomy
In the past, radical cystectomy via open surgery has been
considered the gold-standard treatment for muscle inva-
sive bladder cancer. However, in recent years there has
been a progressive increase in the use of robot-assisted
laparoscopic radical cystectomy [12], which is a challen-
ging procedure suitable for both older and younger pa-
tients [13, 14] that can be improved with specific
training and a skilled robotic team [15]. A recent review
suggested that there are several advantages to the robot-
assisted technique, such as lower blood loss and transfu-
sion rate during surgery, and possibly faster gastrointes-
tinal recovery, and a shorter length of hospital stay [16].
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Studies have mostly found that peri-operative and short-
term outcomes are similar when using robot-assisted
versus open radical cystectomy [17–20], but some data
suggests that assisted radical cystectomy improves
minor, but not major, complications compared to open
surgery [9], especially in terms of lower blood loss and
shorter time to returning to a regular diet [17, 21, 22].
Few data on long-term oncological outcomes are avail-
able; initial studies report comparable outcomes for
robot-assisted versus open radical cystectomy [19, 22–
28]. Data on the long-term functioning of patients is also
sparse, with no studies directly comparing urinary con-
tinence or sexual potency in patients receiving robot-
assisted versus open radical cystectomy [16]. Robot-
assisted radical cystectomy has been reported to cost
more than open surgery due to higher supply costs [12],
although to accurately assess the economic advantages
of each technique, long-term studies that assess cancer
recurrence, readmission rate, rehospitalization, and other
health economic variables are needed.
Need for large scale, multicenter registries
There are currently very few Randomized Control Trials
(RCT) comparing robot-assisted laparoscopic versus open
radical cystectomy [17], and previous non-randomized
studies are hampered by small sample sizes and short
follow-ups. Although RCTs are the preferred study design
for evaluating treatment efficacy there is also a need for
comparison-effective studies, because there are multiple
factors that determine the choice and outcomes of surgical
techniques in real-life clinical settings, including complex
clinical decision making, patient and hospital characteris-
tics, and surgical expertise. The current study aims to pro-
vide data to this rapidly developing field by creating a
nationwide, multicenter registry with two-year post-
surgery follow-up of bladder cancer patients who will
undergo bladder cystectomy, with a comprehensive data
collection on multiple outcomes.
Aims
The aim of the project is to investigate the surgical,
oncological, and functional outcomes of patients with
bladder cancer who undergo radical cystectomy compar-
ing three different surgical techniques (robotic-assisted,
laparoscopic, and open surgery). Pre-, peri- and post-
operative factors will be examined, and participants will
be followed for a period of up to 24months to identify
risks of mortality, oncological outcomes, hospital re-
admission, sexual performance, and continence.
Methods & design
Study design and setting
This article describes the Italian Radical Cystectomy
Registry - “Registro Italiano Cistectomia Radicale (RIC)”.
The trial has been retrospectively registered on
ClinicalTrials.gov on 14/01/2020 with reference number
NCT04228198. The study is an observational, prospect-
ive, multicenter, cohort study to assess patients affected
by bladder neoplasms undergoing radical cystectomy
and urinary diversion. This protocol was developed in
accordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) State-
ment. Twenty-eight participating centers across Italy will
provide data for the study. All centers have a similar
peri-operative pathway; all use enhanced recovery after
surgery (ERAS) protocols. The centers are: Urology
Clinic, University of Bologna; Department of Urology,
AOU Careggi, Florence; European Institute of Oncology
Milan; San Raffaele Hospital, Milan; University Hospital
of Verona; Department of Urology, Policlinico Abano;
Department of Urology, Spedali Civili, Brescia; Depart-
ment of Urology and Kidney Transplantation, University
of Foggia, Foggia; Galliera Hospital, Genova; ASST
Niguarda Metropolitan Hospital, Niguarda; Policlinico
Umberto I, Saproma; Department of Clinical Urology,
University of Perugia; Department of Clinical Urology,
AOUP Cisanello Hospital, Pisa; Department of Clinical
Urology, Palermo University, Palermo; Department of
Clinical Urology, Alessandria Hospital, Alessandria; De-
partment of Clinical Urology, ASST Mantova, Mantova;
Department of Clinical Urology, ASL Abruzzo; Depart-
ment of Clinical Urology Ca Foncello Hospital, Treviso;
Department of Clinical Urology II, Bari University, Bari;
Department of Clinical Urology, Vittorio Emanuele Hos-
pital, Catania; Department of Clinical Urology, Casa Sol-
lievo della Sofferenza, Sgrotondo; Hospital Bassiano,
Bassano; Department of Clinical Urology, Hospital San
Francesco ASL 3, Nuoro; Department of Clinical Ur-
ology, Portogruaro; Department of Clinical Urology,
Biella Hospital, Biella; Department of Clinical Urology
Chioggia Hospital; Ausl Modena; Department of Urology
and Kidney Transplantation, Bianchi-Melacrino-Morelli
Grand Metropolitan Hospital.
Participants
We will include patients with a histologically confirmed
diagnosis of bladder cancer between January 1st 2017
and October 31st 2020, who will be treated in the par-
ticipating medical centers. Eligibility screening will be
conducted by the examining physician according to the
following inclusion criteria: 1) male and female consecu-
tively recruited patients; 2) age ≥ 18 years; 3) histologi-
cally confirmed diagnosis of bladder cancer eligible for
radical cystectomy (according to EAU guidelines [7]) at
date of enrollment; 4) providing written, informed con-
sent. We aim to enroll approximately 1000 patients in
the baseline data collection.
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Ethical issues
Data collection will be conducted in accordance with the
World Medical Association Declaration of Helsinki. All
potential participants will be required to sign an In-
formed Consent form. Ethical permission was received
from the Ethical Committee of the University of Padova
(number: 0042389). The standard of care will remain un-
changed in patients participating in this study.
Database design and management
The Italian Radical Cystectomy Registry is an electronic
registry to prospectively collect the data of patients
undergoing radical cystectomy conducted with any tech-
nique (open, laparoscopic, robotic-assisted), similar to
one used by an International consortium. The protocol
was designed by a Scientific Committee of Italian ex-
perts, who regularly reviews the database and proposes
any relevant changes and integrations that may be useful
for fulfilling the project aims. The database is based on
an online platform. Information from patients will be
collected in a confidential manner, according to Italian
privacy Laws (Decreto Legislativo 196/2003); each pa-
tient will be identified via an anonymous identification
code. Data will be used in an aggregated form. Each in-
dividual center will be responsible for the personal data
collected in relation to the project. The information col-
lected will be registered by the responsible physician in
each center on the internet-based data storage file,
which is accessible via username and password. The data
will be regularly transferred to a global database. The
data will be checked and cleaned by an Epidemiologist
and any data inconsistencies or missing values will be
directly resolved with the individual centers. All data will
be analyzed anonymously. The Steering Committee will
grant access for data analysis to individual researchers
according to requests from the participating centers.
Data collection
Figure 1 illustrates the three phases of the study, and
some of the key data that will be collected.
Phase I: recruitment of participating centers
All clinics and hospitals in Italy that currently carry out
radical cystectomy with all three surgical techniques
were contacted to establish interest in participating in
the study. Participation is on a voluntary basis, and the
centers will receive no additional funding for participat-
ing. A responsible physician in each participating center
will be assigned the role of managing the data collection,
guaranteeing the systematic recruitment of eligible pa-
tients, and supervising collection and coding of data ac-
cording to the web-based data collection form. The
questions used in the data collection form were designed
by the Scientific and Steering Committee and include
pre-specified categories for some questions and open
fields for others, where appropriate. Shortly after the
first date of patient recruitment the Scientific Committee
reviewed a selection of the inputted patient data at each
clinic to ensure homogeneity of reporting and modify
any database issues.
Phase II: enrollment of patients
Urology departments of the participating centers will
identify eligible patients during the recruitment phase
(1st January 2017-31st October 2020) in accordance with
the inclusion criteria. All potential participants will be
given an informative letter explaining details of the study
and will be asked to sign an informed consent form.
After written, informed consent is provided information
will be collected from the patients at the moment of sur-
gical intervention and during follow-up (3, 6, 12, and 24
months after radical cystectomy). Surgical technique will
not be randomized and will be assigned according to the
clinical judgement of the surgeon. All participants will
undergo usual clinical care.
Phase III: follow up
After 3, 6, 12, and 24 months post-surgery, data will be
taken directly from the patients at their follow-up med-
ical visits and entered into the online database. The
physician identifying and recruiting patients will oversee
the completion of the data collection forms during
follow-up, even if the patient is subsequently treated in
another center.
Variables
Data will be collected by the medical team during the
patient’s hospital admission and at clinical visits during
the follow-up. Variables of interest include demographic
variables (age, sex, etc), surgical factors (technique use,
length of surgery, blood loss, type of urinary diversion,
node burden, histological exams, surgical margins etc),
mortality, morbidity (pre-, during- and post-surgery),
oncological results, and functioning (continence and sex-
ual performance) over follow-up, as detailed below. All
health and biological data will be taken in accordance
with usual clinical care of the patients and will be stored
at the participating centers in accordance with national
laws and guidelines.
 Patient data includes sex, date of birth, and body
mass index.
 Pre-operatory data includes the name of the
surgeon, date of operation, and American Society
Anesthesiologists (ASA) physical status classification
system [29]. During the physician’s examination
information from the patient’s medical records and
the physical examination will be used to identify
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Fig. 1 Study phases and summary of key data
Porreca et al. BMC Cancer           (2021) 21:51 Page 5 of 9
comorbid medical conditions (diabetes,
hypertension, cardiopathy, chronic obstructive
pulmonary disease, ransient ischemic attack,
anticoagulant-antiplatelet therapy, and other path-
ologies). The Charlson comorbidity score will be cal-
culated [29]. Preoperative grading and staging of the
bladder neoplasm will be done according to standard
criteria (EAU) including T-stage, G-stage, and pres-
ence of a concomitant carcinoma in situ (CIS). Pre-
operative therapeutic interventions, including
neoadjuvant chemotherapy, palliative cystectomy,
and BCG-instillation will be recorded.
 Peri-operative data. Data on the surgical
procedure will be categorized according to the
technique used for cystectomy (open / robotic-
assisted / laparoscopic) as well as for urinary diver-
sion (open / robotic-assisted / laparoscopic). Type of
urinary diversion (ileal conduit / neobladder recon-
struction / other) will be documented as well as
whether there is a conversion to open surgery, and
the reason for conversion. Total time of surgery as
well as time taken for lymphadenectomy and urinary
diversion (minutes) will be measured, in addition to
milliliters of peri-operative bleeding. We will record
multiple peri-operative data including nerve sparing
(no / unilateral / bilateral), lymphadenectomy (not
performed / bilateral external iliac nodes / bilateral
presacral iliac), pelvic lymph node dissection (no /
limited / standard / extended), partial prostatectomy,
urethrectomy, and whether frozen section ureters
(no / yes normal / CIS left / CIS right) or other fro-
zen sections (no / normal urethra / CIS urethra /
normal bundle) are performed.
 Post-operative and histology data. Post-operative
staging and grading of tumors and CIS, as well as
tumor histology (transitional cell carcinoma (TCC),
adenocarcinoma, or other) and Gleason score [30]
will be recorded. Post-operative pelvic node (total
number and position) will be measured as well as
the presence of prostate cancer in men. Positive
margins for bladder and prostate will be measured.
Number of days in hospital and readmission within
30 days post-surgery will be recoded.
 Immediate (< 30 days) and late (30–90 days)
post-operative complications. In the event of a
patient experiencing post-operative complications,
the following characteristics will be recorded: num-
ber of complication events, time of first complica-
tion event, a description of each complication,
Clavien-Dindo classification of immediate complica-
tions [31], and the date and description of treatment
used. This information will be recorded both for im-
mediate (30 days after surgery) and late (30–90 days
after surgery) post-operative complications.
 Follow up and outcomes. All patients will be
followed for 24 months after surgical intervention to
assess multiple outcomes: mortality, tumor
recurrence, continence, and sexual potency. In the
event of a patient moving to another medical facility
for follow-up treatment, the physician will be re-
sponsible for collecting follow-up data from them,
with the patient’s consent. Follow-up data will in-
clude hospital readmission within 90 days, reopera-
tion within 90 days, and mortality (and cause of
death and autopsy data). In the event of tumor re-
currence, data will be taken on date and localization
of tumor recurrence, and subsequent treatment (ad-
juvant chemotherapy or radiation). Functional out-
comes will include daytime and nighttime
continence and sexual potency rates (at > 6 months
and > 12 months) reported by patients to the
physicians.
Statistical analysis
Data will be cleaned and checked for discrepancies by a
statistician before analysis. In cases of missing data, the
responsible physician will be contacted and requested to
check medical records and data-sheets for missing infor-
mation. Characteristics of patients with missing data will
be examined, and if necessary, sensitivity analysis or
multiple imputation will be used to examine the effect of
missing data on the results. Chi-square and students t-
test will be used to assess differences in categorical and
numerical data, respectively. The four main long-term
outcomes of interest are recurrence-free survival,
cancer-specific survival, overall survival, and functioning
(continence and potency). Cox proportional regression
models with 95% confidence intervals will be used to as-
sess the risk of mortality or tumor recurrence according
to the surgical technique used (open, laparoscopic,
robot-assisted technique for cystectomy and/or urinary
diversion). The exposure variable will be classified into
different categories to also examine changes in surgery
type during the operation (e.g., robot-assisted cystec-
tomy and open surgery urinary diversion versus robot-
assisted for both stages of the intervention). Logistic re-
gression models, with adjustment for follow-up time,
will be used to assess outcomes at different time points
including: i) peri-operative factors (e.g., surgery time,
blood loss, etc); ii) immediate post-operative factors
(number of days in hospital post-operative complications
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etc) and; iii) long-term oncological and functional out-
comes (mortality, tumor recurrence, continence and po-
tency) up to 24 months post-surgery. Multivariable
models will be used, with potential confounders selected
both a-priori and on the basis of meeting the three stat-
istical criteria for confounding (associated with the ex-
posure, associated with the outcome, and not being on
the causal pathway between exposure and outcome).
Stratification and adjustment will be made according to
the medical center, primary surgeon responsible for the
operation and their years of medical experience, and
various pre-surgery factors (tumor grading and staging,
comorbidity, ASA score etc). Sample size is estimated
according to a similar previous protocol [32], which is
based on an overall complication percentage of 65% in
the open radical cystectomy [33] with power set at 80%
and alpha 5%, a sample size of 338 (2 × 169) patients is
required to detect a decrease in the overall complication
rate of 15%, i.e. from 65 to 50%.
Role of the scientific and steering committees
The role of Steering Committee will be to supervise the
planning and implementation of the registry. Specifically,
they: approve the participating centers and the corre-
sponding physician in charge of data collection; conduct
quality control of the data; guide and propose relevant
changes in order to meet the project objectives; analyze
and revise final results to be presented at congresses and
published in scientific papers. Members of the Steering
Committee include: Walter Artibani; Maurizio Brausi;
Franco Gaboardi; Michele Gallucci; Giacomo Novara
and; Angelo Porreca.
The role of the Scientific Committee is to guide even-
tual scientific publications and/or presentation of results
at conferences, and to consult with the Steering Com-
mittee. The committee will ensure that authorship eligi-
bility guidelines are adhered to for all publications. The
members include: Alessandro Antonelli; Aldo Bocciardi;
Riccardo Schiavina; Antonio Celia; Luca Cindolo; Renzo
Colombo and; Andrea Minervini.
Discussion
Summary
The current protocol aims to contribute additional data
to the field concerning the short- and long-term out-
comes of different radical cystectomy surgical techniques
for patients with bladder cancer. Similar registries are
ongoing, for example in the Netherlands [32].
Limitations
The main limitation of the study design is that the treat-
ment arms are not randomized. Clinical reasoning be-
hind treatment choice may affect conclusions, although
the extensive data collection on numerous potentially
relevant factors will allow us to adjust for potential con-
founders. There is some value of comparative-
effectiveness trials such as these, because thereare a
complex range of factors and decision making by both
physicians and patients that affect their choice of surgi-
cal technique, which cannot be assessed in RCTs.
Strengths and relevance
Despite the lack of randomization, there are several ad-
vantages of the current protocol. The current literature
is largely based on non-randomized, retrospective ana-
lysis of clinical data, but our protocol was designed pro-
spectively and will include a much larger sample size
than the currently available studies. The multicenter de-
sign also provides some variation to the data, with 28
clinics all across Italy providing data, thus minimizing
selection bias. Multiple surgeons in multiple clinics will
perform the different surgical techniques on diverse
groups of patients (different regions of the country, so-
cioeconomic groups, rural and urban population etc),
which will increase generalizability of the results.
Though most studies compare two surgical techniques,
we will compare three types (open, laparoscopic, and
robot-assisted). Another novel aspect is that we will per-
form analysis that accounts also for change in technique
during surgery (e.g., robotic-assisted cystectomy plus
open urinary diversion surgery versus robotic-assisted
surgery for both parts of the operation). Importantly, we
have planned a long follow-up of 24 months that will
allow us to examine both the short- and long-term out-
comes in patients. A large proportion of the current evi-
dence focuses on short-term outcomes and data is
sparse on patients’ functional outcomes such as contin-
ence and potency, but we have included up to two-years
of follow-up on multiple factors, including survival,
functioning, and oncological outcomes, thus providing a
more comprehensive picture.
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